"We are a medical research center who works alongside South Florida’s top physicians as medical partners in performing clinical trials that are in phase 1, 2, 3 and 4. We focus on the integrity of all our clinical studies and strictly follow all FDA guidelines for the following focus areas: Asthma, Crohn's Disease, Ulcerative Colitis, Cirrhosis of the Liver, NASH, Fatty Liver, Alzheimer's Disease, Agitation in Alzheimer's Disease, Mild Cognitive Impairment, Bipolar Disorder in Adolescents and Autism Spectrum. We compensate all participants and their doctors for their services for those who qualify."

During the past decade, IMIC Inc. conducted 66 clinical trials. In the 10-year time frame, 66 clinical trials started and 32 clinical trials were completed, i.e. on average, 48.5% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 24 clinical trials were completed. i.e. 109.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IMIC Inc." #1 sponsor was "AstraZeneca" with 7 trials, followed by "Celgene" with 7 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored and "Pfizer" with 5 trials sponsored. Other sponsors include 40 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IMIC Inc." #1 collaborator was "National Institute on Aging (NIA)" with 4 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "APCER Life Sciences" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "IMIC Inc." are "Ulcerative Colitis" (11 trials), "Alzheimer Disease" (10 trials), "Crohn Disease" (5 trials), "Alzheimer's Disease" (4 trials) and "COVID-19" (4 trials). Many other conditions were trialed in "IMIC Inc." in a lesser frequency.

Most popular intervention types in "IMIC Inc." are "Drug" (67 trials), "Other" (8 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (43 trials), "Etrasimod" (5 trials), "Dapagliflozin" (4 trials), "Etrolizumab" (4 trials) and "Ozanimod" (3 trials). Other intervention names were less common.

The vast majority of trials in "IMIC Inc." are 74 trials for "All" genders.

Currently, there are NaN active trials in "IMIC Inc.". undefined are not yet recruiting, 15 are recruiting, 11 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 34 completed trials in IMIC Inc., undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in IMIC Inc., 3 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".